OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

Time Interval from Surgery to Chemo Impacts Prognosis in Ovarian Cancer

Researchers in Austria investigated whether the time interval from surgery to start of chemotherapy has an impact on clinical outcome in patients with advanced serous ovarian cancer.

Data from 191 patients with stage III or IV ovarian cancer who underwent surgery followed by platinum-based chemotherapy were analysed.  The results, which were published in Gynecologic Oncology on July 17, 2013, showed that timing of treatment, residual disease left after surgery, and stage were significant factors for overall survival.  While the interval from surgery to start of chemotherapy did not possess prognostic significance in patients without postoperative residual disease, it significantly correlated with overall survival in patients with postoperative residual disease.

Therefore, the findings suggest that delayed initiation of chemotherapy might compromise overall survival in patients with advanced serous ovarian cancer, especially when suboptimally debulked.

Comments

One Response to “Time Interval from Surgery to Chemo Impacts Prognosis in Ovarian Cancer”